IASO Thessalias, Greece
Background: Obesity is increasingly recognized as a modifiable driver of chronic kidney disease (CKD), rather than simply a comorbidity. Its renal effects arise both directly—through altered intraglomerular haemodynamics, inflammation, activation of the renin–angiotensin–aldosterone system (RAAS), and lipotoxicity—and indirectly, through hypertension, diabetes, and broader cardiovascular–kidney–metabolic (CKM) dysfunction.
Key mechanisms and assessment: Early obesity-related kidney injury may involve hyperfiltration and intraglomerular hypertension, followed over time by declining estimated glomerular filtration rate (eGFR) and glomerular damage. Adipose-tissue inflammation, altered adipokine signalling, ectopic fat deposition, oxidative stress, and sodium retention may further contribute to renal injury. Assessment based on body mass index (BMI) alone is often insufficient, particularly in CKD, where fluid retention and loss of muscle mass can distort interpretation. A more complete assessment can incorporate waist circumference or waist-to-hip ratio, body composition, muscle strength, albuminuria, and kidney-function estimates; cystatin C may be useful when creatinine-based estimates are less reliable.
Clinical implications: Management should be individualized, empathetic, and multidisciplinary, with attention to kidney and cardiovascular protection rather than weight alone. Nutrition adapted to CKD, physical activity including resistance exercise, sleep, and psychosocial support form the foundation of care. Pharmacological strategies are evolving: sodium–glucose cotransporter-2 (SGLT2) inhibitors remain a cornerstone of kidney protection in eligible patients, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained stronger kidney-outcome evidence. In the FLOW trial, semaglutide reduced the risk of the primary composite kidney and cardiovascular outcome in people with type 2 diabetes and CKD. Tirzepatide studies have also reported reductions in albuminuria, although these findings should be interpreted in the context of the study designs and populations. Metabolic and bariatric surgery may be considered for selected patients after careful assessment of kidney function, nutritional status, and perioperative risk.
Conclusion: Recognizing obesity as a therapeutic target creates an opportunity to intervene earlier and more comprehensively in CKD. The clinical priority is to combine accurate risk assessment with sustainable lifestyle support and evidence-based cardiorenal therapies, while monitoring kidney function, albuminuria, volume status, and preservation of muscle mass. Further trials—particularly in people without diabetes and with hard renal endpoints—are needed to clarify the optimal sequencing and combination of treatments.
Dr. Athina Gompou is a Consultant Nephrologist and Scientific Director of the Department of Nephrology and Renal Dialysis/Haemodialysis Unit at IASO Thessaly in Larissa, Greece, where she also maintains a private medical practice. She serves as Vice President of the Larissa Medical Association, representing private physicians. She graduated from Ivan Petrovits Pavlov Medical School in 1996, obtained recognition of her medical degree in Greece and her medical license in 1997, and received her specialty in Nephrology in 2007, along with an ESOT Committee Diploma in Transplantation. Her clinical experience includes nephrology and transplantation at Laiko General Hospital of Athens, as well as rotations in neurology, psychiatry, internal medicine, and rural healthcare. Dr. Gompou has contributed to clinical research published in international medical journals and has presented her work at international scientific conferences.